Antisense oligonucleotide targeting snora71c for treating liver cancer, and use thereof

An antisense oligonucleotide targeting SNORA71C effectively inhibits liver cancer metastasis and growth by regulating non-coding RNA expression, providing a novel therapeutic approach for liver cancer treatment.

WO2026240388A1PCT designated stage Publication Date: 2026-11-19AJOU UNIV IND ACADEMIC COOP FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/005763
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-04-20
Filing Date
2026-04-30
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current treatments for liver cancer, particularly advanced stages, have limited effectiveness due to high metastasis rates and vascular invasion, necessitating the development of novel therapeutic strategies targeting non-coding RNA to regulate cancer metastasis.

Method used

A single-stranded antisense oligonucleotide (ASO) is developed to inhibit the expression of SNORA71C, a non-coding RNA identified as a tumor-promoting factor in liver cancer metastasis, using chemical modifications such as 2'-O-methoxyethyl (MOE) and phosphorothioate bonds, formulated into pharmaceutical and health functional food compositions.

Benefits of technology

The ASO effectively inhibits liver cancer cell growth, metastasis, and neovascularization, reducing tumor burden and improving prognosis by targeting SNORA71C, offering a new therapeutic paradigm for liver cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026005763_19112026_PF_FP_ABST
    Figure KR2026005763_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an antisense oligonucleotide (ASO) targeting SNORA71C for treating liver cancer, and a use thereof. The objective of the present invention is to select a specific ncRNA that is highly expressed in patients with liver cancer metastasis, and develop a new treatment method targeting same. Specifically, SNORA71C, which is a specific non-coding RNA, was discovered by analyzing two public omics liver cancer genome datasets (GSE114564 and TCGA LIHC) capable of identifying the presence of liver cancer metastasis. Through additional functional studies, it has been identified that SNORA71C inhibition using general siRNA does not exhibit a liver cancer inhibitory effect, but a tumor inhibitory effect is exhibited when the newly developed ASO of the present invention is used. Therefore, it has been demonstrated that SNORA71C can be used as a new target molecule for treating liver cancer, and a therapeutic strategy targeting non-coding RNA is expected to present a new paradigm for the treatment and diagnosis of liver cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Antisense oligonucleotide for liver cancer treatment targeting SNORA71C and its use

[0001] The present invention relates to an antisense oligonucleotide for treating liver cancer targeting SNORA71C and its uses.

[0002] Liver cancer is one of the major cancers with high incidence and mortality rates worldwide. It is a disease that is difficult to detect early and has a high likelihood of recurrence even after treatment. In particular, liver cancer easily causes intrahepatic and extrahepatic metastasis, and when metastasis occurs, the prognosis is extremely poor, leading to a sharp decline in the 5-year survival rate. Currently, standard treatments for liver cancer include surgical resection, local treatment, targeted therapies, and immunotherapy; however, treatment responses are limited in patients with advanced liver cancer, making the development of effective treatment strategies an urgent priority.

[0003] Liver cancer metastasis is the process in which cancer cells invade blood vessels and spread inside and outside the liver, and vascular invasion (VI) is one of the key factors determining the prognosis of liver cancer patients. Patients with VI have a higher risk of recurrence than those without it and face a more difficult condition to treat due to a lower response to existing therapies. To overcome this, various treatment strategies are being studied, and research is particularly active in identifying novel molecular targets that can fundamentally regulate the mechanisms of cancer metastasis.

[0004] Non-coding RNA (ncRNA) does not encode proteins but plays a crucial role in regulating gene expression, epigenetic changes, cell signaling, and the tumor microenvironment. In particular, the expression of specific ncRNAs is regulated during the development and progression of cancer, and some ncRNAs have been found to perform tumor-suppressing or tumor-promoting functions. Recent studies suggest that ncRNAs are involved in the survival, growth, metastasis, and acquisition of drug resistance in cancer cells, presenting new possibilities for cancer treatment by regulating these processes.

[0005] Among these, small nuclear RNA (snRNA) is known to be primarily involved in the pre-mRNA splicing process and plays a crucial role in RNA processing and gene expression regulation. However, recent studies report that snRNA is closely linked not only to splicing regulation but also to the progression of cancer. Some snRNAs have been found to be abnormally expressed in cancer cells and to affect cell proliferation, survival, metastasis, and epigenetic regulation.

[0006] Therapeutic strategies targeting non-coding RNA represent an approach differentiated from existing protein-based therapies, offering the advantage of modulating cancer-related pathways that are difficult to target with conventional treatments. Recently, the development of antisense oligonucleotide (ASO), small interfering RNA (siRNA), and microRNA (mRNA)-based therapies has been active, and some ncRNA-targeted therapies are demonstrating their potential through clinical trials. In particular, strategies that inhibit tumor-promoting ncRNA or activate tumor-suppressing ncRNA are attracting attention as therapeutic approaches applicable to various cancers, including liver cancer.

[0007] The objective of the present invention is to provide a composition for the prevention, improvement, or treatment of liver cancer comprising a single strand of antisense oligonucleotide (ASO) that inhibits SNORA71C expression as an active ingredient.

[0008] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of liver cancer comprising a single-stranded ASO that inhibits SNORA71C expression as an active ingredient.

[0009] In addition, the present invention provides a health functional food composition for the prevention or improvement of liver cancer comprising a single strand of ASO that inhibits SNORA71C expression as an active ingredient.

[0010] The present invention relates to an antisense oligonucleotide for the treatment of liver cancer targeting SNORA71C and its use. The aim was to identify a specific ncRNA with increased expression in patients with liver cancer metastasis and to develop a new therapeutic method targeting it. Specifically, SNORA71C, a specific non-coding RNA, was discovered by analyzing two public omics liver cancer genomic datasets (GSE114564, TCGA LIHC) capable of confirming liver cancer metastasis. Through additional functional studies, it was confirmed that while inhibition of SNORA71C using general siRNA did not show an inhibitory effect on liver cancer, a tumor-suppressing effect was observed when using the antisense oligonucleotide (ASO) newly developed in this invention. This demonstrated that SNORA71C can be utilized as a new target molecule for liver cancer treatment, and it is expected that therapeutic strategies targeting non-coding RNA will present a new paradigm for the treatment and diagnosis of liver cancer.

[0011] Figure 1 shows the results of selecting genes that showed significant changes in expression in each dataset after analyzing differentially expressed ncRNAs in patients with liver cancer metastasis (VI) in the GSE114564 and TCGA_LIHC datasets.

[0012] Figure 2 shows the results confirming that SNORA71C expression was increased in patients with liver cancer metastasis (VI).

[0013] Figure 3 shows the results of the analysis of the predictability of liver cancer metastasis of SNORA71C.

[0014] Figure 4 shows the analysis results indicating that SNORA71C is tumor-specifically upregulated in patients with resectable hepatocellular carcinoma and is evaluated as a molecular marker closely associated with aggressive clinical characteristics such as imaging and pathological staging, vascular invasion, and distant metastasis.

[0015] Figure 5 shows the results confirming the knockdown ability of siRNA against SNORA71C.

[0016] Figure 6 shows the results of verifying the knockdown ability of ASO against SNORA71C.

[0017] Figures 7 and 8 show the results of verifying the ability of SNORA71C's siRNA and ASO to control liver cancer cell growth.

[0018] Figure 9 shows the results of verifying the function of siRNA in regulating liver cancer cell metastasis against SNORA71C.

[0019] Figure 10 shows the results of verifying the function of ASO in regulating liver cancer cell metastasis against SNORA71C.

[0020] Figure 11 shows the verification results of the metastasis control ability of SNORA71C in a mouse lung metastasis model.

[0021] The present invention provides a pharmaceutical composition for the prevention or treatment of liver cancer comprising a single strand of ASO that inhibits ASNORA71C expression as an active ingredient.

[0022] Preferably, the ASO may be represented by SEQ ID NO. 5 or SEQ ID NO. 6, but is not limited thereto.

[0023] Preferably, the ASO may have one or more sugar structures or base structures of ribonucleic acids or binding sites between ribonucleic acids chemically modified, and more preferably, the ASO may include a 2'-O-methoxyethyl (MOE) modification or a phosphorothioate bond, but is not limited thereto.

[0024] Preferably, the pharmaceutical composition can inhibit the metastasis of liver cancer, but is not limited thereto.

[0025] The pharmaceutical composition or complex formulation of the present invention may be prepared using pharmaceutically suitable and physiologically acceptable adjuvants in addition to the active ingredient, and the adjuvants may include solubilizing agents such as excipients, disintegrants, sweeteners, binders, coating agents, leavening agents, lubricants, lubricants, or flavoring agents. The pharmaceutical composition of the present invention may preferably be formulated as a pharmaceutical composition by including one or more pharmaceutically acceptable carriers in addition to the active ingredient for administration. As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, which are sterile and biocompatible, saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these components may be used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed. In addition, by additionally adding diluents, dispersants, surfactants, binders, and lubricants, it can be formulated into injectable formulations such as aqueous solutions, suspensions, and emulsions, as well as pills, capsules, granules, or tablets.

[0026] The pharmaceutical formulation forms of the pharmaceutical composition of the present invention may be granules, powders, coated tablets, tablets, capsules, suppositories, syrups, juices, suspensions, emulsions, drops, or injectable liquids, as well as sustained-release formulations of the active compound. The pharmaceutical composition of the present invention may be administered in a conventional manner via intravenous, intra-arterial, intraperitoneal, intramuscular, intrasternal, transdermal, nasal, inhalation, topical, rectal, oral, intraocular, or intradermal routes. The effective amount of the active ingredient in the pharmaceutical composition of the present invention refers to the amount required for the prevention or treatment of a disease. Accordingly, it may be adjusted according to various factors including the type of disease, the severity of the disease, the type and content of the active ingredient and other ingredients contained in the composition, the type of formulation, the patient's age, weight, general health status, gender and diet, the time of administration, the route of administration and the secretion rate of the composition, the duration of treatment, and concurrently used drugs.

[0027]

[0028] In addition, the present invention provides a health functional food composition for the prevention or improvement of liver cancer comprising a single strand of ASO that inhibits SNORA71C expression as an active ingredient.

[0029] Preferably, the ASO may be represented by SEQ ID NO. 5 or SEQ ID NO. 6, but is not limited thereto.

[0030] Preferably, the ASO may have one or more sugar structures or base structures of ribonucleic acids or binding sites between ribonucleic acids chemically modified, and more preferably, the ASO may include a 2'-O-methoxyethyl (MOE) modification or a phosphorothioate bond, but is not limited thereto.

[0031] Preferably, the above health functional food composition can inhibit the metastasis of liver cancer, but is not limited thereto.

[0032] The health functional food composition of the present invention may be provided in the form of powder, granules, tablets, capsules, syrup, or beverage, and the health functional food composition may be used in combination with other foods or food additives in addition to the active ingredient, and may be used appropriately according to conventional methods. The amount of the mixture of the active ingredient may be appropriately determined according to the purpose of use, for example, prevention, health, or therapeutic treatment.

[0033] The effective dose of the active ingredient contained in the above health functional food composition may be used in accordance with the effective dose of the above pharmaceutical composition, but in the case of long-term consumption for the purpose of health and hygiene or health control, it may be less than the above range, and it is certain that the active ingredient may be used in an amount greater than the above range because there is no problem in terms of safety.

[0034] There are no special restrictions on the types of health foods mentioned above, and examples include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes.

[0035]

[0036] Meanwhile, the antisense oligonucleotide according to the present invention may be subject to various modifications that a person skilled in the art can conceive, but such modifications fall within the scope of the present invention as long as the base sequence itself is not changed. Here, the degree to which the base sequence itself is not changed means that at least 90% of the base sequence is maintained even if a part of the 5' end or 3' end of the base sequence or a part of the intermediate sequence is added, replaced, or deleted.

[0037] As an example of the above modification, even if the binding site between nucleic acids has modifications such as phosphorothioate, thiophosphoramidate, phosphonate, or methylphosphonate, as long as the base sequence does not change, it does not deviate from the scope of the present invention. In addition, even if the nucleic acid structure is chemically modified with 2'-O-Methoxyethyl (2'-MOE), 2′-Fluoro, 2'-O-Methyl (2'-OMe), LNA (locked nucleic acid), PNA (Peptide Nucleic Acid), PMO (phosphoramidate morpholino oligomer), N3′-P5′ phosphoramidates, 2′-deoxy-2′-fluoro-β-D-arabino nucleic acid analogue (FANA), cyclohexene nucleic acids (CeNAs), tricyclo-DNA (tcDNA), 2-thiothymidine, 3′-fluorohexitol nucleic acid (FHNA), ethylene-bridged nucleic acid (ENA), (S)-constrained ethyl (cEt) modification, etc., as long as the base sequence does not change, it does not deviate from the scope of the present invention. The base portion may be 5-methyl pyrimidine as needed, and even if additional fluoro groups are modified, it likewise does not deviate from the scope of the invention.

[0038] Hereinafter, the present invention will be described in detail with reference to examples to aid in understanding. However, the following examples are merely illustrative of the content of the present invention and the scope of the present invention is not limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to those with average knowledge in the art.

[0039]

[0040] <Experimental Example>

[0041] The following experimental examples are intended to provide experimental examples that are commonly applied to each embodiment according to the present invention.

[0042]

[0043] 1. Screening of ncRNAs associated with liver cancer metastasis

[0044] The GSE114564 and TCGA_LIHC datasets contain information on the presence of vascular invasion (VI) in liver cancer patients, so the two transcriptome datasets were collected and analyzed.

[0045] Differentially expressed genes (DEGs) were selected based on p-value < 0.05 and log2FC ≥ 0.3 by comparing the non-metastatic (NVI) versus metastatic (VI) patient groups in each dataset.

[0046] Analysis of genes with altered expression in both datasets revealed that SNORA71C, a small nuclear RNA (snRNA) family of ncRNAs, showed significantly increased expression in VI patients.

[0047] Through this, SNORA71C was identified as a candidate with potential as an oncogene associated with liver cancer metastasis.

[0048]

[0049] 2. Cell Culture

[0050] Human liver cancer cell lines (Huh-7, PLC / PRF / 5, SNU449) were purchased from the Korean Cell Line Bank (Seoul, Korea) and cultured in RPMI-1640 medium containing 10% FBS (Gibco, USA) and 100 units / mL penicillin-streptomycin (Gendepot, USA). The medium was replaced every 3 to 4 days, and the cells were cultured under conditions maintained at 5% CO2 and a temperature of 37°C.

[0051]

[0052] 3. siRNA synthesis and transfection

[0053] Among the siRNAs for transfection, the control siRNA was synthesized at Genolution (Seoul, Korea). SNORA71C siRNA is Silencer, a product manufactured and sold by Thermo Fisher Scientific (Waltham, MA, USA). ® Select siRNA products and siRNA synthesized by Genolution with free design support from BIONICS (Seoul, Korea) were used. The nucleotide sequences of each siRNA are shown in Table 1 below.

[0054] RNA duplexes Sense sequence Sequence Source control siRNAUUCUCCGAACGUGUCACGUUU (Sequence No. 1)SNORA71CsiRNA(1)CAUUCGAAAGUGAUCAUGA (Sequence No. 2)Thermo Fisher scientific SNORA71CsiRNA(2)CUGCAUUCGAAAGUGAUCA (Sequence No. 3)BIONICS SNORA71CsiRNA(3)GAGCACUUCCCCGUGUUUG (Sequence No. 4)BIONICS

[0055] Transfection was performed using Lipofectamine 2000 (Invitrogen) reagent at a final siRNA concentration of 200 nM.

[0056]

[0057] 4. Production of antisense oligonucleotides (ASOs) and transfection

[0058] For transfection, an ASO was designed by applying the RNA modification method to the 2'-MOE modified RNA sequence and synthesized by Bioneer (Daejeon, Korea). The sequence information is shown in Table 2 below.

[0059] ASOSequenceSNORA71CASO(1)5'-zA*zU*zG*zA*zU-*c*a*c*t*t*t*c*g*a*a*-zU*zG*zC*zA*zG-3' (SEQ ID NO: 5) SNORA71CASO(2)5'-zC*zC*zA*zA*zA-*c*a*c*g*g*g*g*a*a*g*-zU*zG*zC*zU*zC-3' (SEQ ID NO: 6)

[0060] zA: [2'-MOE(A)], zG: [2'-MOE(G)], zC: [2'-MOE(C)], zU: [2'-MOE(U)], *: phosphorothioate

[0061] Transfection was performed using Lipofectamine 2000 (Invitrogen) reagent at a final ASO concentration of 50 nM.

[0062]

[0063] 5. qRT-PCR

[0064] cDNA synthesis was performed using the PrimeScript™ RT Master Mix (Perfect Real Time) kit (TaKaRa, Shiga, Japan).

[0065] RNA isolated from cells and RNase-free water were combined to make 8 µl, and 2 µl of PrimeScript™ RT Master Mix was added for a total of 10 µl to proceed with cDNA synthesis.

[0066]

[0067] The conditions for cDNA synthesis were set as follows.

[0068] A. Stage 1: 37℃, 15 minutes

[0069] B. Stage 2: 85℃, 4℃ after 5 seconds, -ing

[0070]

[0071] qRT-PCR was performed using primers with the sequences below. The primers used were synthesized by IDT (Hanam, Korea). 5 µl of qRT-PCR Master Mix (2X, High ROX) (Gendepot, TX, USA) was used, and qRT-PCR was performed with a total volume of 10 µl.

[0072]

[0073]

[0074] GeneAccession No.Forward sequenceReverse sequenceSNORA71CNR_003017.25'-CCCCTGCATTCGAAAGTGAT-3'(Sequence No. 7)5'-AGGGTTTGGAAGAGACAGGAG-3'(Sequence No. 8)GAPDHNM_002046.65'-AGTATGACAACAGCCTCAAG-3'(Sequence No. 9)5'-TCATGAGTCCTTCCACGATA-3'(Sequence No. 10)

[0075]

[0076] The qRT-PCR conditions were set as follows.

[0077] A. Stage 1: 95℃, 2 minutes

[0078] B. Stage 2: 95℃, 15 seconds

[0079] C. : 58℃, 34 seconds

[0080] D. : 72℃, 30 seconds

[0081] E. Repeat Stage 2 for 40 cycles

[0082]

[0083] 6. Cell Growth Analysis

[0084] Cells were seeded into a 60mm culture dish to fill it about 30%, transfected, cultured for a certain period of time, and then the number of each cell was measured.

[0085] 4–6 × 10⁻⁶ in a 6-well plate 3After evenly dispensing the transfected cells of dogs, they were cultured in a medium containing FBS at 37°C. After the time conditions set for each cell had elapsed, the cells were fixed at room temperature with 1% paraformaldehyde and then stained with 0.5% crystal violet solution to observe colony formation ability.

[0086]

[0087] 7. Wound Healing Analysis

[0088] Transfected cells were dispensed into a 6-well plate, and when the plate was filled to about 90–100%, scratches were made using a micropipette tip. Afterward, images of the scratched areas were observed under a microscope.

[0089]

[0090] 8. Cell Infiltration Analysis

[0091] Cell infiltration analysis was performed using a Matrigel (BD Bioscience) coating.

[0092] For infiltration analysis, Matrigel was diluted to a concentration of 0.3 mg / mL, 100 µl was dispensed onto the insert, and the samples were incubated at 37°C for 2 hours. Subsequently, cells transfected with ASO were applied to the insert, and the samples were cultured using a medium containing 2.5–5% FBS as a chemical attractant.

[0093] After the time conditions set for each cell had elapsed, the infiltrating cells were stained and observed under a microscope.

[0094]

[0095] 9. In vitro analysis of neovascularization

[0096] As neovascularization is an essential process necessary for the survival, growth, and metastasis of cancer cells, the inhibitory ability on neovascularization was evaluated by performing a tube formation assay through the co-culture of human umbilical vein endothelial cells (HUVEC) and liver cancer cells.

[0097] Inject 200 µl of Matrigel into a 24-well plate and polymerize at 37°C for at least 1 hour, then add 1.5 × 10⁻⁶ into the wells 6 Two HUVEC cells were inoculated, and an equal number of transfected liver cancer cells were inoculated into the insert and cultured for 17 hours. Images were obtained by observing the cultured HUVEC cells under a microscope.

[0098]

[0099] 10. Lung metastasis mouse model (tail vein injection model)

[0100] 1.5×10 for a tail vein injection model to confirm the metastatic potential of liver cancer cells 6 Canine transfected cells were mixed with serum-free media, and the cell suspension was injected into the tail vein of 6-week-old Athymic mice at the beginning and after 3 weeks.

[0101] The body weight of the mice was measured twice a week, and the mice were sacrificed 21 weeks after the first injection to check for liver cancer cells that had metastasized to the lungs.

[0102]

[0103] <Example 1> Data Analysis for Screening of Metastatic Liver Cancer-Related ncRNAs

[0104] As a result of analyzing differentially expressed ncRNAs in patients with liver cancer metastasis (VI) in the GSE114564 and TCGA_LIHC datasets, genes that showed significant changes in expression in each dataset were selected.

[0105] A total of 831 ncRNAs were selected from GSE114564, and 478 ncRNAs were selected from TCGA_LIHC (Fig. 1).

[0106] Fifty-three (4.2%) ncRNAs were identified as having changes in expression in both datasets, and among them, SNORA71C, a small nuclear RNA (snRNA) family, was found to have increased expression in patients with liver cancer metastasis (VI). This suggests that SNORA71C is closely associated with liver cancer metastasis and is a candidate gene likely to play a tumor-promoting role (Fig. 2).

[0107]

[0108] <Example 2> Analysis of the Predictability of Liver Cancer Metastasis of SNORA71C

[0109] Receiver Operating Characteristic (ROC) curves were analyzed to compare the expression patterns of selected ncRNAs from the GSE114564 and TCGA_LIHC datasets.

[0110] In the GSE114564 data, the AUC (Area Under the Curve) value of SNORA71C was 0.67, showing statistically significant predictive power, and the AUC value in TCGA_LIHC was also 0.69, confirming a consistent trend.

[0111] The two datasets suggested that SNORA71C expression can distinguish between the VI (vascular infiltration) and NVI (non-metastatic) patient groups.

[0112] This implies that SNORA71C has a high potential to be used as a biomarker to predict liver cancer metastasis, and it is necessary to evaluate its potential as a therapeutic target through additional functional studies (Fig. 3).

[0113]

[0114] SNORA71C expression was evaluated by qRTPCR in 84 patients who underwent hepatectomy at Ajou University Hospital. The results showed that SNORA71C expression in tumors was generally increased compared to control liver tissue, and in about two-thirds (67%) of the patients, the tumor-to-non-tumor ratio was greater than 1 (Fig. 4A). This suggests that SNORA71C is already elevated in a significant number of resectable hepatocellular carcinomas.

[0115] In the same-patient expression analysis, SNORA71C expression was significantly higher in tumor tissue (T) compared to non-tumor liver tissue (NT), and in the ROC analysis distinguishing between NT and T, it showed discriminative power at the level of AUC 0.62 and P=0.007 (Fig. 4B). Although it has moderate performance as a single diagnostic marker, there is room for clinical application considering the possibility of combining it with other metastasis-related indicators.

[0116] In preoperative image-based BCLC staging analysis, SNORA71C expression was significantly higher in advanced stage (BD) compared to early stage (0-A), and the ROC AUC for advanced stage prediction was 0.71 (95% CI 0.59-0.84, P=0.01) (Fig. 4C). This suggests that SNORA71C can be utilized as a candidate for a non-invasive stage prediction biomarker, as it is selectively upregulated in patients with radiographically advanced hepatocellular carcinoma.

[0117] In the pathological pUICC stage, SNORA71C expression was significantly increased in stages III-IV compared to stages I-II, and the ROC AUC predicting postoperative high stage (III-IV) was 0.73 (95% CI 0.62-0.84, P<0.001) (Fig. 4D). This implies that SNORA71C can function as a molecular marker reflecting the elevation of the final pathological stage, i.e., histological progression.

[0118] Depending on the presence of vascular invasion at the time of blood collection, SNORA71C expression was significantly higher in patients with vascular invasion, and the ROC AUC for predicting vascular invasion was 0.68 (95% CI 0.56-0.79, P=0.005) (Fig. 4E). In addition, high SNORA71C expression was also observed in patients with metastasis at the time of blood collection, and the ROC AUC for distinguishing the presence or absence of metastasis was 0.73 (95% CI 0.61-0.86, P=0.004), showing superior performance compared to the simple NT vs. T distinction (AUC 0.62) (Fig. 4F). This suggests that SNORA71C is a metastasis-associated marker that better reflects aggressive tumor behaviors such as vascular invasion and metastasis than the mere presence of the tumor.

[0119] In summary, SNORA71C was evaluated as a molecular marker that is not only tumor-specifically upregulated in patients with resectable hepatocellular carcinoma but is also closely associated with aggressive clinical characteristics such as imaging and pathological staging, vascular invasion, and distant metastasis. These results support the view that SNORA71C is a metastasis-related biomarker reflecting the tumor biological malignancy of hepatocellular carcinoma, as well as a promising target for future applications in risk classification via blood-based quantification and pre- and post-operative monitoring.

[0120]

[0121] <Example 3> Confirmation of the knockdown ability of siRNA and ASO against SNORA71C

[0122] To confirm the siRNA knockdown effect of SNORA71C, three types of siRNAs of control and SNORA71C were transfected into liver cancer cell lines to check the knockdown efficiency of SNORA71C. It was confirmed that none of the three types of siRNAs acted on the knockdown of SNORA71C even when treated at a high concentration of 200 nM (Fig. 5).

[0123] Meanwhile, when the knockdown efficiency was confirmed by transfecting liver cancer cell lines with SNORA71C ASOs, it was confirmed that both types of ASOs effectively reduced the expression of SNORA71C, unlike siRNA, which had no knockdown effect (Fig. 6).

[0124]

[0125] <Example 4> Verification of the liver cancer cell growth control ability of SNORA71C's siRNA and ASO

[0126] To determine whether it affects the growth potential of liver cancer cells, SNORA71C was transfected with siRNA and ASO to check cell morphology and measure cell count. As a result, it was confirmed that siRNA did not affect cell growth (Fig. 7A), while ASO reduced the number of cells (Fig. 7B).

[0127] In addition, when comparing the colony-forming ability of liver cancer cells, it was confirmed that colony formation decreased compared to the experimental control group when ASO was transfected (Fig. 8).

[0128]

[0129] <Example 5> Verification of the liver cancer cell metastasis regulatory function of SNORA71C's siRNA and ASO

[0130] To determine whether SNORA71C is involved in liver cancer cell metastasis, wound healing analysis was performed after transfecting with siRNA and ASO, and it was confirmed that SNORA71C siRNA treatment did not affect the wound healing ability of liver cancer cells (Fig. 9).

[0131] When liver cancer cells were transfected with SNORA71C's ASO, unlike with siRNA, it was confirmed that the wound healing ability (Fig. 10A), motility, and invasiveness of the liver cancer cells were significantly reduced compared to the experimental control group (Fig. 10B).

[0132] In addition, as a result of confirming the expression of EMT markers, stem cell markers, and angiogenesis markers using western blot, it was confirmed that the expression of the epithelial cell markers Occludin and Claudin 1 increased, while the expression of the mesenchymal cell markers Fibronectin and Snail decreased. It was also confirmed that the expression of the stem cell markers Nanog, Oct-4, and CD133, as well as the angiogenesis markers CD31 and HIF-1a, were significantly decreased in both cell lines (Fig. 10C).

[0133] As a result of confirming the ability to inhibit neovascularization through a tube formation assay, it was confirmed that tube formation was inhibited by significantly reducing the number of nodes and the mesh area in HUVEC cells co-cultured with liver cancer cells transfected with ASO (Figs. 10D and 10E).

[0134]

[0135] <Example 6> Verification of SNORA71C’s Metastasis Control Ability in a Mouse Lung Metastasis Model

[0136] When the ability of SNORA71C to control liver cancer metastasis was confirmed using a mouse lung metastasis model, it was confirmed that in the experimental group injected with tail veins of cells with reduced SNORA71C expression, the number of nodules in the lungs was reduced and lymph node metastasis was also reduced (Fig. 11).

[0137]

[0138] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

1. A pharmaceutical composition for the prevention or treatment of liver cancer comprising a single-stranded antisense oligonucleotide (ASO) that inhibits SNORA71C expression as an active ingredient.

2. A pharmaceutical composition for the prevention or treatment of liver cancer according to claim 1, wherein the ASO is represented by SEQ ID NO. 5 or SEQ ID NO.

6.

3. A pharmaceutical composition for the prevention or treatment of liver cancer according to claim 1, wherein the ASO is characterized by having a sugar structure or base structure of one or more ribonucleic acids, or a binding site between said ribonucleic acids, chemically modified.

4. A pharmaceutical composition for the prevention or treatment of liver cancer according to claim 3, characterized in that the ASO comprises a 2'-O-methoxyethyl (MOE) modification or a phosphorothioate bond.

5. A pharmaceutical composition for the prevention or treatment of liver cancer, characterized in that, in any one of claims 1 to 4, the pharmaceutical composition inhibits the metastasis of liver cancer.

6. A health functional food composition for preventing or improving liver cancer comprising a single-stranded ASO that inhibits SNORA71C expression as an active ingredient.

7. A health functional food composition for preventing or improving liver cancer, characterized in that, in claim 6, the ASO is represented by SEQ ID NO. 5 or SEQ ID NO. 6.